NCT04435106View on ClinicalTrials.gov

Compassionate Use of Opaganib in Patients With Coronavirus Disease 2019 (COVID-19)

CompletedOBSERVATIONAL
Enrollment

23

Participants

Timeline

Start Date

April 3, 2020

Primary Completion Date

May 1, 2020

Study Completion Date

May 15, 2020

Conditions
Coronavirus Infections
Interventions
DRUG

Opaganib

Study participants received opaganib 2 x 250 mg capsules (500 mg) every 12 hours in addition to Standard of Care

DRUG

Standard of Care

Study participants received Standard of Care

Trial Locations (1)

9103102

Shaare-Zedek Medical Center, Jerusalem

All Listed Sponsors
lead

Shaare Zedek Medical Center

OTHER

NCT04435106 - Compassionate Use of Opaganib in Patients With Coronavirus Disease 2019 (COVID-19) | Biotech Hunter | Biotech Hunter